Global stock

XETRAEUR

Merck KGaA

MRK.DE

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

61/ 100

Overall score·MRK.DE

Current price

143.3EUR

23/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E 15,6 a EV/EBITDA 12,4 působí relativně příznivě, zatímco trailing P/E 25,9 a PEG 2,22 ukazují na méně přesvědčivou valuaci; hodnota je proto přibližně neutrální. Růst zisků i ziskovost jsou oslabené, zatímco stabilitu podporuje nízká beta a přiměřená likvidita a momentum zůstává mírně pozitivní díky ceně nad 50denním i 200denním průměrem.

§ Outlook vs S&P 500Next 12 months

About the same

Estimated chance of beating the index: about 50%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Merck KGaA (MRK.DE) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

61/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

69/100

Slightly positive signal based on current news, price action and the economy.

57/100

A lower score means the stock is expensive relative to the company's earnings and assets.

73% above fair value

An estimate of what the stock should be worth based on the company's future cash.

+3%

How fast the company's revenue grows year on year.

55/100

How much the company earns from each unit of revenue and from invested capital.

72/100

Debt level, share-price volatility and how resilient the company is in bad times.

68/100

AI estimate of management quality, execution and capital allocation.

78/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

Kai Beckmann vede společnost jako CEO a předseda představenstva; Helene von Roeder je CFO. Danny Pinhas Bar-Zohar řídí Healthcare a Jean Charles Wirth Life Science. Skupina kombinuje vývoj léčiv s dodávkami pro biovýrobu a elektronický průmysl.

Articles about Merck KGaA, in Czech (2)

Merck nabídne za Silence Therapeutics 1,3 miliardy dolarů v hotovosti

Merck KGaA se dohodl na převzetí Silence Therapeutics za 1,3 miliardy dolarů v hotovosti a za každou její ADS nabízí 20 dolarů. Akcie cílové společnosti po oznámení vyskočily o 125,58 %, dokončení transakce se očekává v prvním čtvrtletí 2027.

20 October 2026· 2 min

Merck čelí patentovému útesu u klíčového léku Keytruda, konkurence přichází s novými terapiemi

Společnost Merck (MRK) se připravuje na ztrátu patentové ochrany u svého hlavního imunoterapeutika Keytruda, což může ohrozit její tržní postavení. Nové protinádorové léky od konkurence však slibují výraznější pokrok, což může ovlivnit budoucí příjmy firmy.

22 July 2026· 4 min

§ Upcoming results

12 November 2026

in 16 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Merck KGaA (MRK.DE)?

Merck KGaA (MRK.DE) is a global stock traded on XETRA. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Merck KGaA price today?

As of 23 October 2026, Merck KGaA trades at about 143.30 EUR per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Merck KGaA?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Merck KGaA pay a dividend?

Merck KGaA either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Merck KGaA a good investment in 2026?

Our AI signal currently rates Merck KGaA as slightly positive (score 69/100). Financial health comes out at 61/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 73 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Merck KGaA

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

§ More in the article

20/10 · 2 min

Merck nabídne za Silence Therapeutics 1,3 miliardy dolarů v hotovosti

Open article →

/ 100

● Slightly positive

News summary

Older news

Signal 20/10, 04:02

Merck nabízí za Silence Therapeutics prémii 130 %; zpráva uvádí prudký růst akcií cílové firmy. Pokud transakce postoupí podle plánu, může podpořit strategický růst Mercku, její dopad však závisí na dokončení akvizice.

Růst ceny Mercku za 7 i 30 dní a rostoucí trend s RSI 65 podporují krátkodobý výhled. Akvizice přináší růstovou možnost, ale vysoká volatilita a nejisté dlouhodobé přínosy omezují celkové hodnocení.

Risks: Zpoždění či zrušení transakce nebo slabší vývoj hlavního podnikání by mohl pozitivní výhled oslabit.

More about the signal

Risks: Zpoždění či zrušení transakce nebo slabší vývoj hlavního podnikání by mohl pozitivní výhled oslabit.

Signal history· 2

10/1003:0154 · Neutral
BofA Securities 9. října snížila cílovou cenu Mercku z 166 na 163 USD a ponechala doporučení Buy; jde o mírně příznivý rating, ale nižší cílová cena tlumí jeho pozitivní vyznění. Dopad by podpořilo potvrzení příznivého hodnocení dalšími podklady, zatímco další snižování odhadů by jej oslabilo.
01/1019:0171 · Strongly positive
V globálních zprávách se objevují možnosti u Merck KGaA v souvislosti s biotechnologickými inovacemi a očekávaným růstem zisku. Podnikové novinky a makro prostředí mohou podporovat cenový trend směrem vzhůru.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Overvalued73% above fair value

82.79

range 65.1 – 108.5

Current price

143.30 EUR

23 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

82.79 EUR

range 65.1 EUR – 108.5 EUR

: 4.0%
: 8.5%
: 4.54 EUR

Předpokládaný růst FCF 4 % p.a. je konzervativní vzhledem k růstu tržeb 3 % a poklesu EPS; počítá s mírným zlepšením, nikoli s rychlou expanzí. Diskontní sazba 8,5 % zohledňuje relativně nízkou betu, ale také zadlužení a nejistotu kolem vývoje ziskovosti. Terminální růst 2,5 % odpovídá dlouhodobému tempu ekonomiky.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

1/ 6

6/6 tests available

1. Below DCF fair value

73.1% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

91% above the 1-year low (102.8 EUR to 147.5 EUR), based on stored daily prices.

4. P/E vs. similar companies

P/E 25.9 vs. median 26.7 (71 companies).

5. P/E relative to growth

PEG 2.2; a lower value means cheaper growth.

6. Analyst price target

7.6% vs. the current price, 14 analysts.

Price vs DCF

Current price

143.3 EUR

Low 65.07 EURHigh 108.5 EUR

Current priceDCF midpoint: 82.79 EUR

Price vs analyst target

Current price

143.3 EUR

Low 135.0 EURHigh 179.0 EUR

Current priceAverage: 154.2 EUR

DCF gap

above range

73.1% above the DCF midpoint (82.79 EUR).

Analyst target

+7.6%

Average target 154.2 EUR vs. price 143.3 EUR.

Analyst consensus

Target range

135.0 EUR - 179.0 EUR

Coverage

14 analysts

Analyst consensus

2.1 / 5

Changes 180 d

+0 / -0

EPS next year

5.9%

Revenue next year

5.4%

Valuation multiples

25.9

15.6

2.0

2.9

12.4

2.2

52-week range91% above the low

102.8 EUR147.5 EUR

-25.0%

3.0%

11.2%

8.1%

Price vs 50D4.4%

Price vs 200D12.0%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení prosazuje restrukturalizaci, efektivitu a kapitálovou disciplínu; nízké riziko auditu a odměňování podporuje hodnocení, které však mírně snižují slabší práva akcionářů.

strong

Široké portfolio ve vědách o živé přírodě, zdravotnictví a elektronických materiálech spolu s dlouhou historií a odborným know-how vytváří významnou konkurenční výhodu.

Information

Type: Global stock
Symbol: MRK.DE
Exchange: XETRA
Currency: EUR
Sector: Healthcare
: 25.9x
: 60.3B USD
: 40.6 %
: 0.79

§ Risk profile

Výsledky mohou kolísat podle klinického úspěchu léčiv, investiční aktivity zákazníků v Life Science a cyklické poptávky po polovodičových materiálech. Český investor navíc nese měnové riziko EUR/CZK.

Ask the AI about Merck KGaA All signals